Koyfin Home > Directory > Health Care > Revance Therapeutics > Long-term Debt / Equity

Revance Therapeutics Long-term Debt / Equity Chart (RVNC)

Revance Therapeutics annual/quarterly Long-term Debt / Equity from 2012 to 2020.
  • Revance Therapeutics Long-term Debt / Equity for the quarter ending June 06, 2020 was $77m a 77.16% increase of 60m year over year
  • Revance Therapeutics Long-term Debt / Equity for the last 12 months ending June 06, 2020 was $77m a 77.16% increase of 60m year over year
  • Revance Therapeutics Annual Long-term Debt / Equity for 2019 was $11m a 90.79% increase of 10m from 2018
  • Revance Therapeutics Annual Long-term Debt / Equity for 2016 was $1m a -99.67% decrease of -1m from 2015
  • Revance Therapeutics Annual Long-term Debt / Equity for 2015 was $2m a 83.94% increase of 2m from 2014
Other Ratios Metrics:
  • Revance Therapeutics Total Debt / Capital for the quarter ending March 03, 2018 was $0m a -426.67% decrease of -2m year over year
  • Revance Therapeutics Other Liabilities for the quarter ending September 09, 2018 was $19m a 68.91% increase of 13m year over year
  • Revance Therapeutics Total Debt / Equity for the quarter ending March 03, 2018 was $0m a -436.21% decrease of -2m year over year
View Chart On Koyfin

Quarterly RVNC Long-term Debt / Equity Data

06/2020$77m
03/2020$64m
12/2019$11m
09/2019$18m
06/2019$15m
03/2019$13m
03/2017$1m
12/2016$1m
09/2016$1m
06/2016$2m

Annual RVNC Long-term Debt / Equity Data

2019$11m
2016$1m
2015$2m
2014$0m
2013$-8m
2012$-9m
2011$-108m